publication date: Dec. 4, 2020
NCI Trials for December 2020
The National Cancer Institute approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase 0 – 10401
A Phase 0 Window-of-Opportunity Pharmacodynamic Trial of Triapine (NSC# 663249) in Uterine Corpus Serous Adenocarcinoma
JHU Sidney Kimmel Comprehensive Cancer Center LAO
Stone, Rebecca Lynn
Phase I – 10387
Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients with HIV Infection
Albert Einstein College of Medicine EDDOP
Phase II – AALL1821
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse
Children’s Oncology Group
Cooper, Stacy L.
Phase II – S2001
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations
Phase III – EA8183
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
ECOG-ACRIN Cancer Research Group
Morgans, Alicia Katherine
Phase III – S1931
Phase III Trial … Continue reading NCI Trials for December 2020
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.